Skip to main navigation Skip to search Skip to main content

Isolated Limb Perfusion for Melanoma

  • Bin B. R. Kroon
  • , Eva M. Noorda
  • , Bart C. Vrouenraets
  • , Gooike W. van Slooten
  • , Omgo E. Nieweg
  • Antoni van Leeuwenhoek Hospital
  • Slotervaart Hospital
  • Onze Lieve Vrouwe Gasthuis

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Isolated limb perfusion with high-dose chemotherapy is an accepted treatment modality to achieve locoregional control in advanced melanoma of the extremities. The drug of choice is melphalan. Tumor necrosis factor-α is frequently added to melphalan in bulky disease, and this combination may be an option for repeat perfusion for recurrent melanoma after a first perfusion. Results of perfusions performed with tissue temperatures between 37°C and 38°C seem to be equivalent to those of the perfusions performed under mild hyperthermic conditions. Perfusion cannot be recommended as an adjunct to wide local excision in patients who have primary melanoma. Adjuvant perfusion in repeatedly recurrent limb melanoma, however, may be of value because it lengthens the limb recurrence-free interval and decreases the number of lesions per recurrence significantly. Regional toxicity of perfusion should be mild when risk factors are taken into account. © 2008 Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)785-794
JournalSurgical oncology clinics of North America
Volume17
Issue number4
DOIs
Publication statusPublished - Oct 2008
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Isolated Limb Perfusion for Melanoma'. Together they form a unique fingerprint.

Cite this